Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bimekizumab→

Bimekizumab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1418205-77-2
Molecular formula
Not available
Molecular weight
Not available
Drug class
Humanised monoclonal antibodydual interleukin-17A and interleukin-17F inhibitor
Mechanism of action
Selectively binds and neutralises IL-17A and IL-17F, preventing their interaction with the IL-17 receptor complex and reducing downstream inflammatory signalling.
Indications / reported uses
  • Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
  • Treatment of active psoriatic arthritis in adults
  • Treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation and active ankylosing spondylitis in adults; exact eligibility and indications are product- and jurisdiction-specific

Sources: US FDA prescribing information — BIMZELX · EMA EPAR — Bimzelx · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Bimekizumab Environmental Risk Assessment (ERA) (the Bimekizumab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.